Centre Hospitalier Universitaire de Treichville

7XVV+5P4, Abidjan, Côte d’Ivoire

Public hospital

Serves Western Africa

The Centre Hospitalier Universitaire de Treichville (CHU Treichville) is one of four public cancer hospitals in Abidjan, Côte d’Ivoire, and the only hospital in the region with a Department of Infectious and Tropical Diseases. CHU Treichville serves as a referral center for patients across much of the country, as cancer and infectious disease diagnostic and treatment services are limited outside of Abidjan. The hospital has previously hosted Phase II and III clinical trials for infectious diseases and has international research connections with institutions in West Africa, the US, and Europe.

Links to previous clinical trials:
https://classic.clinicaltrials.gov/ct2/show/NCT01715922

https://classic.clinicaltrials.gov/ct2/show/NCT04022967

https://classic.clinicaltrials.gov/ct2/show/NCT00495651

Site Capabilities

Clinical Trial Experience

Therapeutic area interests:

  • Cancer
  • Infectious disease

    • Institution has received grant(s) from:

  • National Funder(s)
  • International Funder(s)

    • Sponsors for previous clinical trials include:

  • Academic
  • Government
  • Industry
  • Investigator-initiated

    • Previous clinical trials conducted:

  • Behavioral
  • Diagnostic
  • Drug – biologic
  • Drug – small molecule
  • Epidemiological
  • Observational
  • Surgical
  • Vaccine

    • Study phase capabilities:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

    • Pediatric research capabilities:

  • Yes

    • Institution Regulatory/Research Ethics Committees

    Frequency of meetings: Monthly

    Application turnaround time (IRB/IEC): 3-4 weeks

    Average time from receipt of final protocol to review and approval of study by all relevant committees: 3-4 weeks

    Additional compliance:

  • IRB/IEC in compliance with IC E6(R2) in terms of composition, functions, and operations guidelines
  • Institution and/or local regulation mandates the distribution of study safety reports to IRB/IEC

    • Institution Staffing Resources

    Staff typeStaff available (y/n) and specialty experience
    Research coordinatorYes
    -Training in Good Clinical Laboratory Practice (GCLP)
    Research nurseNot available
    Research data managerNot available
    Quality assurance managerYes
    -Training in Good Clinical Laboratory Practice (GCLP)
    BiostatisticiansYes
    Database programmersYes
    -Training in Good Clinical Practice (GCP)
    EpidemiologistsYes
    -Training in Good Clinical Practice (GCP)
    PathologistsYes
    PharmacistsYes
    -Training in Good Clinical Laboratory Practice (GCLP)

    Institution Diagnostic Capabilities

  • Institution has personnel capable of performing diagnostic biopsies

    • Biopsies performed on-site:

  • Core needle biopsy
  • Endoscopic biopsy
  • Fine needle aspirate
  • Liquid biopsy
  • Sentinel lymph node biopsy
  • Skin biopsy
  • Surgical biopsy

    • Laboratory basics:

  • Institution has a laboratory on site
  • Institution sends diagnostic samples to external laboratory
  • Institution’s laboratory has been inspected or audited

    • Laboratory accreditations:

  • None

    • Tests performed on-site:

  • Complete blood count (CBC) with differential
  • Comprehensive metabolic-chemistry panel (CMP)
  • Routine urinalysis
  • Antibody tests
  • Antigen tests
  • Antimicrobial susceptibility and sensitivity
  • Bacterial smear and culture
  • Flow cytometry
  • Fluorescent in situ hybridization (FISH)
  • Fungal culture
  • Genetic testing
  • Histology
  • Immunohistochemistry (IHC)
  • Laboratory-developed tests (LDTs)
  • Microscopy
  • Ova and parasite (O&P) test
  • PCR and/or RT-PCR
  • Other nucleic acid amplification tests (NAATs)
  • Viral culture
  • Viral load

    • Imaging capabilities:

  • Computed tomography (CT)
  • Magnetic resonance imaging (MRI)
  • Positron emission tomography (PET)
  • Nuclear imaging
  • Ultrasound
  • X-ray
  • Pediatric imaging
  • Other: Mammography

    • Institution Research Systems, Recordkeeping, and Data Management

  • Institution adheres to informed consent processes compliant with ICH E6(R2)
  • Institution follows ICH E6(R2) for collection and storage of source documentation for paper and/or electronic records
  • Institution stores patient records/source documents (paper/electronic) in a secured, limited access location during and after the trial
  • For source documents collected via electronic data capture, institution has a validated system and site procedures that follow ICH E6(R2) 5.5 guidelines
  • Institution has process in place for proper storage, archiving, and retrieval of essential study document per ICH 8.1
  • Institution study monitors have full access to source documents or certified copies of source documents (if electronic) if direct access can’t be obtained
  • Institution has a finance administration team
  • Institution undergoes routine financial audits

    • Institution Pharmacy

  • Pharmacy on site
  • Pharmacy has secure, limited access storage area with daily temperature monitoring and backup generator
  • Pharmacy has standard processes in place to ensure proper receipt, handling, and storage of investigational study drug/vaccine and comparators
  • Pharmacy has standard processes in place to ensure proper dispensing
  • Pharmacy has standard processes in place to ensure proper labeling that maintains the study blind
  • Pharmacy has standard processes in place to ensure proper drug/vaccine accountability, retrieval, and return or destruction of unused product
  • Institution has a secure, limited-access investigational drug/vaccine storage area with daily temperature monitoring
  • Institution’s pharmacy has a backup generator sufficient to run necessary equipment, refrigerators, freezers, etc.

    • Institution Equipment

  • Protocol for managing anaphylactic shock
  • Institution has a blood bank
  • Institution carries out blood transfusions for patients that need it
  • Functioning IV infusion pumps
  • Functioning basic life support equipment (crash cart)
  • Functioning electrocardiogram (EKG)

    • Availability of banked blood at institution:

  • Always available
  • Occasionally available
  • Rarely available

    • Institution performs the following routine blood screening tests on banked blood:

  • HIV
  • HBV
  • HCV
  • HPV
  • HTLVI
  • HTLVII
  • Syphilis

    • Additional information:

  • Institution’s equipment is calibrated and maintained per manufacturer’s guidelines
  • Institution’s equipment calibration and maintenance is documented
  • Institution’s laboratory has a secure, limited access biological specimen storage area with daily temperature monitoring
  • Institution’s laboratory has a backup power source, with alarm, sufficient to run necessary equipment, refrigerators, freezers, etc.
  • Institution maintains and uses a diagnostic imaging protocol manual
  • Laboratory maintains and uses a laboratory protocol manual
  • Laboratory maintains and uses a laboratory protocol manual

    • Program-Specific Capabilities

    Institution Cancer Treatment Capabilities and Equipment

  • Treats cancer patients
  • Performs surgical excisions
  • Administers chemotherapy
  • Uses radiation therapy

    • Radiotherapy machines on site:

  • Linear accelerator
  • Cobalt 60
  • Brachytherapy machine

    • Institution Infectious Disease Treatment Capabilities and Equipment

  • Treats infectious disease patients
  • Protocol for managing sepsis

    • Vaccines administered on site:

  • Tetanus
  • Hepatitis B
  • Seasonal Flu

    • Infectious disease treatment services performed on site:

  • Antimicrobial/antibiotic drugs (small molecules or biologics; including antibacterial, antifungal, antiparasitic, antiviral medicines)
  • Immunotherapies: Interferon
  • Supportive care/symptom management
  • Surgery
  • Viral load monitoring

    • Investigators at Centre Hospitalier Universitaire de Treichville

    N’da Marcelin Homian, M.D.

    Medical Oncologist, Department of Oncology; Head of Hospitalization Unit

  • Cancer

    • Overview

    Dr. Homian is a Medical Oncologist and Head of the Hospitalization Unit in the Department of Oncology at Centre Hospitalier Universitaire de Treichville. In addition to his M.D., he has a master’s degree in human biology (immunology-allergology stream). His clinical trial interests include behavioral, diagnostic, drug (small molecule), epidemiological, and observational studies for breast cancer and prostate cancer. He is the principal investigator and co-investigator on multiple initiatives focused on improving breast cancer diagnosis in Côte d’Ivoire.

    Formal Clinical Trial Training*

  • Formal GCP Training
  • Formal HSP Training

    • Experience Conducting or Participating in Clinical Trials: No

    Kouame Konan Yvon Kouassi, M.D.

    Medical Oncologist, Department of Oncology; General Manager, Department of Oncology

  • Cancer

    • Overview

    Prof. Kouassi is a Medical Oncologist and General Manager in the Department of Oncology at Centre Hospitalier Universitaire de Treichville. In addition to his M.D., he has a master’s degree in pharmacology and expertise in genetics. His clinical trial interests include behavioral, diagnostic, drug (biologic and small molecule), epidemiological, and observational studies for breast, colon, liver, and prostate cancers. He is the coordinator of a future Phase II clinical trial of a new treatment for advanced triple-negative breast cancer in Côte d’Ivoire, as well as a study of biological determinants of certain symptoms among prostate cancer patients.

    Formal Clinical Trial Training*

  • Formal GCP Training

    • Experience Conducting or Participating in Clinical Trials: No

    Mohamed Kouyaté, M.D.

    Medical Doctor, Pathologist, and Professor of Pathology

  • Cancer
  • Infectious Diseases

    • Overview

    Prof. Kouyaté is a Medical Doctor, Pathologist, and Professor of Pathology at Centre Hospitalier Universitaire de Treichville. He has a keen interest in teaching and research to build pathology capacity in Côte d’Ivoire. He also has expertise in biostatistics, data management, database programming, laboratory medicine, pediatric infectious diseases, pediatric oncology, quality assurance, research coordination, and research management. Prof. Kouyaté’s clinical trial interests include diagnostic, epidemiological, and observational studies for cancer (breast, colorectal, liver, prostate, and skin) and infectious diseases (Buruli ulcer, histoplasmosis, mycetoma, and tuberculosis).

    Formal Clinical Trial Training*

  • Formal HSP Training
  • Formal GCLP Training

    • Experience Conducting or Participating in Clinical Trials: No

    Mohamed Kassir Agnide Madiou, M.D.

    Clinician in Medical Oncology, Department of Oncology

  • Cancer

    • Overview

    Dr. Madiou is a clinician specializing in medical oncology in the Department of Medical Oncology at Centre Hospitalier Universitaire de Treichville. He is a member of the Department team responsible for organizing and managing multidisciplinary consultation meetings. He has published three scientific articles about chemotherapy-induced febrile neutropenia, lymphoma, and sexuality in breast cancer patients. His clinical trial interests include diagnostic, drug (biologic), and observational studies for bladder, breast, colorectal, liver, and prostate cancers.

    Formal Clinical Trial Training*

  • Formal GCP Training

    • Experience Conducting or Participating in Clinical Trials: No

    Fèmi Perez Odidi, M.D.

    Medical Oncologist

  • Cancer

    • Overview

    Dr. Fèmi Perez Odidi is a resident in the Department of Medical Oncology at Centre Hospitalier Universitaire de Treichville. His areas of expertise, and clinical trial interests, include medical oncology, with a focus on breast, prostate, gynecological (cervical), and digestive (colorectal, gastric) cancers; cancer epidemiology and biostatistics; cancer biology; and implementation of software solutions in healthcare facilities. Dr. Odidi conducted a study to assess the management of breast cancer surgical specimens in Benin in 2020, and contributed to a pioneer study of HLA-DR expression in breast cancer patients in Côte d’Ivoire in 2022. He is currently an investigator on the Ivorian team of the African Cancer Study, conducting the first-ever genetic characterization of solid cancers in West Africa.

    Formal Clinical Trial Training*

  • Formal GCP Training

    • Experience Conducting or Participating in Clinical Trials: No

    Bitti Addé Odo, M.D.

    Medical Oncologist

  • Cancer

    • Overview

    Dr. Odo is a Medical Oncologist in the Department of Oncology at Centre Hospitalier Universitaire de Treichville and is responsible for managing multidisciplinary consultation meetings in the Department. In addition to his M.D., he is pursuing a master’s degree in human biology (biochemistry-molecular biology option) and training in pharmacology and therapeutic assessment. He has a background in clinical research and has research papers in development on cancer in Côte d’Ivoire, particularly HER2-positive and RH-positive breast cancer. His clinical trial interests include diagnostic, drug (biologic and small molecule), and observational studies for bladder, breast, colorectal, kidney, liver, and prostate cancers and sarcoma.

    Formal Clinical Trial Training*

  • Formal GCP Training

    • Experience Conducting or Participating in Clinical Trials: No

    Fleur Audrey Sessegnon, M.D.

    Medical Oncologist, Department of Oncology

  • Cancer

    • Overview

    Dr. Sessegnon is a Medical Oncologist in the Department of Oncology at Centre Hospitalier Universitaire de Treichville. She is responsible for medical student training in the hospital’s Hospitalization Unit and medical meeting group. She has expertise in laboratory medicine and is completing a master’s degree in human biology (molecular biology stream). Her clinical trial interests include diagnostic, epidemiological, and observational studies focused on:

    • Breast, colorectal, and prostate cancers, due to their high prevalence, generally late diagnosis, and lack of existing clinical trial data in Côte d’Ivoire.
    • Relationships between infectious diseases (including hepatitis B, HIV, and malaria); antibiotic resistance; and cancer. 

    Formal Clinical Trial Training*

  • Formal HSP Training
  • Formal GCP Training

    • Experience Conducting or Participating in Clinical Trials: No

    *Definitions

    • HSP – Human Subjects Protection
    • GCP – Good Clinical Practice
    • GCLP – Good Clinical Laboratory Practice